ANTIVIRAL MATERIAL , ANTIVIRAL FILM, ANTIVIRAL FIBER, AND ANTIVIRAL PRODUCT

• US 20120201861A1
• Filed: 02/09/2012
• Published: 08/09/2012
• Est. Priority Date: 08/12/2009
• Status: Active Grant

• Current Assignee: Kabushiki Kaisha Toshiba (Toshiba Corporation), Toshiba Materials Company Limited (Toshiba Corporation)
• Original Assignee: Kabushiki Kaisha Toshiba (Toshiba Corporation), Toshiba Materials Company Limited (Toshiba Corporation)
• Inventors: NAKANO, Kayo, Sato, Akira, Kusaka, Takao, Kasamatsu, Shinya, Sasaki, Akito, Fukushi, Daisuke
• Granted Patent: US 8,741,349 B2
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A01N 25/12 Powders or granules A01N25/26 takes precedence
• CPC Class Codes: A01N 59/16 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: B01J 21/063 Titanium; Oxides or hydroxides thereof
• CPC Class Codes: B01J 21/066 Zirconium or hafnium; Oxides or hydroxides thereof
• CPC Class Codes: B01J 23/30 Tungsten
• CPC Class Codes: B01J 23/34 Manganese
• CPC Class Codes: B01J 23/6527 Tungsten
• CPC Class Codes: B01J 23/888 Tungsten
• CPC Class Codes: B01J 35/30 characterised by their physical properties
• CPC Class Codes: B01J 35/39 Photocatalytic properties
• CPC Class Codes: B01J 35/40 characterised by dimensions, e.g. grain size in a colloidal state B01J35/23; crystallite size B01J35/77
• CPC Class Codes: B01J 35/58 Fabrics or filaments
• CPC Class Codes: B01J 35/612 less than 10 m2/g
• CPC Class Codes: B01J 35/613 10-100 m2/g
• CPC Class Codes: B01J 35/615 100-500 m2/g
• CPC Class Codes: B01J 35/617 : 500-1000 m2/g
• CPC Class Codes: B01J 37/0201 : Impregnation
• CPC Class Codes: B01J 37/0215 : Coating
• CPC Class Codes: B01J 37/04 : Mixing B01J37/0009, B01J37/0018 take precedence
• CPC Class Codes: B01J 37/349 : making use of flames, plasmas or lasers
• CPC Class Codes: C03C 17/006 : with materials of composite character
• CPC Class Codes: C03C 2217/42 : consisting of particles only
• CPC Class Codes: C03C 2217/70 : Properties of coatings
• CPC Class Codes: Y10T 428/2982 : Particulate matter [e.g., sphere, flake, etc.]

Abstract

In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=logC−logA], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 1× for 24 hours.

Claims

1. An antiviral material comprising at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles,

wherein the microparticles, which are undergone a test to evaluate a virus titer by inoculating on a specimen, to which the microparticles are adhered in a range of not less than 0.01 mg/cm² nor more than 40 mg/cm², at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating with visible light having a wavelength of 380 nm or more and illuminance of 6000 1×

for 24 hours by using a white fluorescent lamp and an ultraviolet cutting filter, by a method based on Test method for antibacterial activity of photocatalytic products under photoirradiation and efficacy of JIS-R-1702 (2006), have an inactivation effect R of 1 or more expressed by following;

R=logC−

logA

where, C denotes a virus titer TCID obtained after irradiating an unprocessed specimen with the visible light for 24 hours, and A denotes a virus titer TCID50 obtained after irradiating the specimen having the microparticles with the visible light for 24 hours.

2. The antiviral material according to claim 1,

wherein the inactivation effect R is 2 or more.

3. The antiviral material according to claim 1,

wherein the inactivation effect R when the illuminance of the visible light in the test is set to 1000 1×

is 1 or more.

4. The antiviral material according to claim 1,

wherein the inactivation effect R when an irradiation time of the visible light in the test is set to 4 hours is 0.5 or more.

5. The antiviral material according to claim 1,

wherein the microparticles have a mean primary particle diameter (D50) in a range of 1 to 200 nm.

6. The antiviral material according to claim 1,

wherein the microparticles have a BET specific surface area in a range of 4.1 to 820 m²/g.

7. The antiviral material according to claim 1,

wherein the microparticles contains 15% or more of microparticles having a primary particle diameter of 40 nm or less.

8. The antiviral material according to claim 1,

wherein the microparticles satisfy any one of conditions (1) to (3) described below when the microparticles are measured by X-ray diffractometry:

(1) only a first peak exists in 2θ

range from 22.5°

to 25°

, and a half value width of the peak is 1°

or more;

(2) a first peak and a second peak exist in 2θ

range from 22.5°

to 25°

, and an intensity of a valley between the peaks is 10% or more of an intensity of the first peak; and

(3) a first peak, a second peak, and a third peak exist in 2θ

range from 22.5°

to 25°

, and an intensity of a lowest valley among valleys each between the peaks is 10% or more of an intensity of the first peak.

9. The antiviral material according to claim 1,

wherein the tungsten oxide composite contains a transition metal element in a range of 0.01 to 50 mass %.

10. The antiviral material according to claim 1,

wherein the tungsten oxide composite contains at least one metal element selected from Ti, Zr, Mn, Fe, Pd, Pt, Cu, Ag, Zn, Al, and Ce in a range of 0.01 to 50 mass %.

11. The antiviral material according to claim 1,

wherein the tungsten oxide composite contains at least one metal element selected from Cu, Ag, and Zn in a range of 0.01 to 1 mass %.

12. The antiviral material according to claim 10,

wherein the metal element is contained in the tungsten oxide composite in at least one form selected from a single element, a compound, and a complex compound with tungsten oxide.

13. An antiviral film comprising the antiviral material according to claim 1.

14. The antiviral film according to claim 13, further comprising an inorganic binder in a range of 5 to 95 mass %.

15. The antiviral film according to claim 13,

wherein a thickness of the antiviral film is in a range of 2 to 1000 nm.

16. An antiviral fiber comprising the antiviral material according to claim 1.

17. An antiviral product comprising the antiviral material according to claim 1.

18. The antiviral product according to claim 17,

wherein the antiviral product is configured to be used under irradiation of visible light having illuminance of 1000 1×

or less.

19. The antiviral product according to claim 17,

wherein the antiviral product is configured to be a product exhibiting antiviral performance against at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1), and a swine influenza virus.

20. An antiviral product comprising the antiviral film according to claim 13.

21. An antiviral product comprising the antiviral fiber according to claim 16.